

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
 Stylesheet Version v1.2

EPAS ID: PAT5580551

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	ASSIGNMENT
CONVEYING PARTY DATA	
Name	Execution Date
CARNOT, LLC	06/17/2019
RECEIVING PARTY DATA	
Name:	IMBRIA PHARMACEUTICALS, INC.
Street Address:	17511 LOS MORROS #2283
City:	RANCHO SANTA FE
State/Country:	CALIFORNIA
Postal Code:	92067
PROPERTY NUMBERS Total: 4	
Property Type	Number
Application Number:	62298977
Application Number:	62449708
Application Number:	62449722
PCT Number:	US2017019000
CORRESPONDENCE DATA	
Fax Number:	(617)856-8201
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>	
Phone:	6178568132
Email:	ip@brownrudnick.com
Correspondent Name:	ADAM M. SCHOEN, ESQ.
Address Line 1:	BROWN RUDNICK LLP
Address Line 2:	ONE FINANCIAL CENTER
Address Line 4:	BOSTON, MASSACHUSETTS 02111
ATTORNEY DOCKET NUMBER:	IMBR-009
NAME OF SUBMITTER:	ADAM M. SCHOEN
SIGNATURE:	/ADAM M. SCHOEN/
DATE SIGNED:	06/19/2019
Total Attachments: 5	
source=IMBR-009-Asmt-CARN-IMBR#page1.tif	
source=IMBR-009-Asmt-CARN-IMBR#page2.tif	

source=IMBR-009-Asmt-CARN-IMBR#page3.tif

source=IMBR-009-Asmt-CARN-IMBR#page4.tif

source=IMBR-009-Asmt-CARN-IMBR#page5.tif

PATENT

REEL: 049522 FRAME: 0756

ASSIGNMENT

WHEREAS I, Authorized Signatory of Assignor,

CARNOT, LLC

hereinafter referred to as "Assignor(s)" having all rights, title, and interest to the "Invention(s)" set forth in in Exhibit A;

WHEREAS, IMBRIA PHARMACEUTICALS, INC., whose post office address is 17511 Los Morros, #2283, Rancho Santa Fe, CA 92067 (the "Assignee"), is desirous of acquiring the entire right, title, and interest in: the Inventions; the applications for patent identified in Exhibit A; the right to file applications for patent of any country on the Inventions; any application for patent of any country claiming priority to these applications; any provisional or other right to recover damages, including royalties, for prior infringements of these patents applications; and any patent of any country that may be granted therefor or thereon.

NOW, THEREFORE, for good and sufficient consideration, the receipt of which is hereby acknowledged, and to the extent that the Assignor has not done so already via a prior agreement with the Assignee, or if the Assignor has already done so via a prior agreement with the Assignee then in confirmation of any obligation to do so in said prior agreement, the Assignor has sold, assigned, transferred, and set over, and by these presents does sell, assign, transfer, and set over, unto the Assignee, its successors, legal representatives, and assigns, the Assignor's entire right, title, and interest in:

- (a) the Invention(s);
- (b) the application for patent identified n Exhibit A;
- (c) the right to file applications for patent of any country on the Invention(s), including all rights under the Paris Convention for the Protection of Industrial Property and under the Patent Cooperation Treaty;
- (d) any application(s) for patent of any country claiming the Invention(s);
- (e) any application(s) for patent of any country claiming priority to the application for patent identified in Exhibit A or any application(s) for patent claiming the Invention(s), including any division(s), continuation(s), and continuation(s)-in-part; and
- (f) any provisional or other right to recover damages, including royalties, for prior infringements of any application for patent identified in the preceding paragraphs (b)-(e); and

(g) any patent(s) of any country that may be granted for or on any application for patent identified in the preceding paragraphs (b) – (e), including any reissue(s) and extension(s) of said patent(s).

The above-granted rights, titles, and interests are to be held and enjoyed by the Assignee, for its own use and behalf and the use and behalf of its successors, legal representatives, and assigns, as fully and entirely as the same would have been held and enjoyed by the Assignor had this sale and assignment not been made.

The Assignor hereby represents to the Assignee, its successors, legal representatives, and assigns, that, at the time of execution and delivery of these presents, or if applicable, at such time said prior agreement was executed, the Assignor is a lawful owner of an undivided interest in the entire right, title, and interest in and to the Invention(s), that the Invention(s) are unencumbered, except, if applicable, by obligation to assign in accordance with said prior agreement, and that the Assignor has good and full right and lawful authority to sell and convey the same in the manner set forth herein.

The Assignor hereby covenants and agrees to and with the Assignee, its successors, legal representatives, and assigns, that the Assignor will sign all papers and documents, take all lawful oaths, and do all acts necessary or required to be done in connection with any and all proceedings for the procurement, maintenance, enforcement and defense of the Invention(s), said applications, and said patents, including interference proceedings, without charge to the Assignee, its successors, legal representatives, and assigns, but at the cost and expense of the Assignee, its successors, legal representatives, and assigns.

The Assignor hereby requests the patent authority to issue/grant said patents of their respective country to the Assignee for the sole use and behalf of the Assignee, its successors, legal representatives, and assigns.

Date: June 17, 2019

By: *Andrew D. Levin*
CARNOT, LLC

Name: Andrew D. Levin

Title at Assignor: President

Date: June 19, 2019

By: 
Witness Signature

By: Heidi Henson
Witness Name

Date: June 17, 2019

By: Ebun Garner
IMBRIA PHARMACEUTICALS, INC.

Name: Ebun Garner

Title at Assignee: Chief Legal Officer

Date: June 19, 2019

By: 
Witness Signature

By: Heidi Henson
Witness Name

EXHIBIT A

Docket No.	Jurisdiction	Application No.	Filing Date	Publication No.	Title
IMBR-009/00US 34944/38	US	62/298977	February 23, 2016	n.a.	COMBINATION THERAPY
IMBR-009/01US 34944/39	US	62/449708	January 24, 2017	n.a.	COMBINATION THERAPY
IMBR-009/02US 34944/40	US	62/449722	January 24, 2017	n.a.	COMBINATION THERAPY
IMBR-009/02WO 34944/29	PCT	PCT/US2017/019000	February 23, 2017	WO 2017/147220	COMBINATION THERAPY
IMBR-009/03EP 34944/31	EP	17757163	February 23, 2017	3419959	COMBINATION THERAPY
IMBR-009/03US 34944/30	US	16/078325	August 21, 2018	n.a.	COMBINATION THERAPY

63426424 v.1

PATENT

REEL: 049522 FRAME: 0761

RECORDED: 06/19/2019